Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR443820 in adults with amyotrophic lateral sclerosis
2021-004156-42Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing SAR443820 with Placebo (2 arms). Primary endpoint: Change from baseline in the ALSFRS-R total score (Part A). Started Dec 2021; status: completed.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-004156-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004156-42.